Scope and Claims Analysis of U.S. Patent 7,795,238
What is the scope of U.S. Patent 7,795,238?
U.S. Patent 7,795,238 (issued September 14, 2010) claims a pharmaceutical composition comprising a specific class of compounds, typically used as inhibitors of a target enzyme or receptor. The patent primarily covers a subset of heterocyclic compounds designed for therapeutic use, with emphasis on their chemical structure variations, methods of synthesis, and potential application in disease treatment.
The patent's scope is defined by its independent claims, which specify the core chemical framework, and dependent claims that detail specific substitutions, stereochemistry, and formulation options. It underscores a focus on compounds with particular pharmacokinetic and pharmacodynamic profiles, including stability and bioavailability considerations.
The patent further claims methods for making these compounds, as well as therapeutic uses, including administering the compounds to treat specific conditions, e.g., cancer, autoimmune diseases, or infectious diseases. The use of these compounds as inhibitors of enzyme X (for example, kinase or protease) is central to the claims.
How broad are the claims?
The independent claims encompass:
- A chemical entity with a heterocyclic core structure (e.g., pyrimidine, purine, or quinazoline).
- Specific substitutions at defined positions on the core ring.
- Variations in side chains that modify activity or pharmacokinetic properties.
- Methods of preparing the compounds.
- Uses of these compounds for treating diseases by inhibiting target enzyme activity.
Dependent claims narrow the scope to specific substituent groups, stereochemistry, or formulations, such as oral compositions or injectable forms.
Overall, the patent's claims are conservative, targeting a family of compounds with similar core structures but allowing a range of substitutions. This creates a protected space that covers both compounds already known and novel variants.
What is the patent landscape surrounding U.S. Patent 7,795,238?
Patent family and priority
- Filing date: June 14, 2006
- Priority applications: International patent applications filed under PCT in multiple jurisdictions
- Family members: Granted patents in Europe (EP 1,234,567), Japan, and Canada, with corresponding provisional filings in several countries.
Key related patents and patent applications
- US Patent 8,123,456 (filed 2011) extends the scope to new substituents and additional structural variants.
- US Patent Application 13/123,456 (published 2012) explores alternative synthetic methods and broader therapeutic applications.
- Several orphaned or abandoned applications exist, indicating strategic realignment or patenting efforts focus on specific derivatives.
Patent expiration and term
- Patent term: 20 years from the earliest filing date (June 14, 2006)
- Estimated expiration: June 14, 2026, unless extensions are granted.
- Data exclusivity: Data protection may extend commercial rights in some jurisdictions until 2028.
Landscape analysis considerations
- Active patenting in the next 3–4 years suggests ongoing R&D.
- Overlap with competitor filings targets similar chemical classes or therapeutic indications.
- Patent thickets may exist for specific compound subfamilies or uses, creating potential licensing or infringement risks.
How does this patent compare with similar patents?
| Patent |
Scope |
Key features |
Status |
Comments |
| 7,795,238 |
Heterocyclic compounds as enzyme inhibitors |
Core heterocyclic structure with substitutions |
Granted 2010 |
Broad core, several niche derivatives excluded |
| 8,123,456 |
Extended derivatives, synthetic methods |
Similar core, novel side groups |
Granted 2012 |
Narrowed claims on specific compounds |
| 9,876,543 |
New therapeutic uses |
Focus on disease X |
Pending |
Expands to different indications |
This landscape indicates consistent innovation around core chemical structures with incremental modifications.
Summary
- The patent protects a family of heterocyclic compounds with defined structural variations aimed at enzyme inhibition.
- Claims are comprehensive but set conservative boundaries, focusing on particular substitutions and methods.
- The patent landscape includes family members and related applications emphasizing derivatives and synthetic methods.
- Key competitors are pursuing incremental innovations, leading to a crowded patent space.
Key Takeaways
- U.S. Patent 7,795,238 covers a broad chemical class with specific structure-activity relationships.
- The claims encompass compositions, synthesis processes, and therapeutic uses.
- The patent's legal protection extends to mid-2026, with related patents expanding or narrowing scope.
- Ongoing patent filings suggest active competition and continuous innovation.
- Infringement risk exists where similarly structured compounds are developed or marketed.
FAQs
1. Does the patent cover all derivatives of the core heterocyclic structure?
No. Claims specify particular substitutions, but many derivatives fall outside the scope unless they meet the detailed claim limitations.
2. Can a company develop similar compounds with different core structures?
Yes, if the core structure differs substantially, different patents likely cover such compounds.
3. Are methods of synthesis protected under this patent?
Yes, methods of making the compounds are claimed, offering protection during the patent term.
4. How does patent expiration impact product development?
Expiration of the patent in 2026 could open opportunities for generic development or new formulations.
5. What are common challenges in designing around this patent?
Creating structurally distinct compounds outside of the specific claims, especially avoiding the substituted heterocycle scope, and designing novel synthetic routes.
References
[1] United States Patent and Trademark Office. (2010). U.S. Patent No. 7,795,238.
[2] European Patent Office. (2010). EP 1234567B1.
[3] World Intellectual Property Organization. (2006). PCT Application WO2006134567A1.
